000			02021 a2200565 4500
005			20250518093841.0
264		0	_c20210108
008			202101s 0 0 eng d
022			_a1573-7217
024	7		_a10.1007/s10549-020-05604-7 _2doi
040			_aNLM _beng _cNLM
100	1		_aDenys, Hannelore
245	0	0	_aSafety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer. _h[electronic resource]
260			_bBreast cancer research and treatment _cMay 2020
300			_a97-105 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Agents, Immunological _xadministration & dosage
650	0	4	_aBelgium
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aCarcinoma, Ductal, Breast _xdrug therapy
650	0	4	_aCarcinoma, Lobular _xdrug therapy
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aInjections, Subcutaneous
650	0	4	_aIsrael
650	0	4	_aMaximum Tolerated Dose
650	0	4	_aMiddle Aged
650	0	4	_aPrognosis
650	0	4	_aProspective Studies
650	0	4	_aReceptor, ErbB-2 _xmetabolism
650	0	4	_aReceptors, Estrogen _xmetabolism
650	0	4	_aReceptors, Progesterone _xmetabolism
650	0	4	_aTrastuzumab _xadministration & dosage
650	0	4	_aYoung Adult
700	1		_aMartinez-Mena, Corina L
700	1		_aMartens, Marc T
700	1		_aD'Hondt, Randal G
700	1		_aGraas, Marie-Pascale L
700	1		_aEvron, Ella
700	1		_aFried, Georgeta
700	1		_aBen-Baruch, Noa E
700	1		_aVulsteke, Christof
700	1		_aVan Steenberghe, Mona M
773	0		_tBreast cancer research and treatment _gvol. 181 _gno. 1 _gp. 97-105
856	4	0	_uhttps://doi.org/10.1007/s10549-020-05604-7 _zAvailable from publisher's website
999			_c30808081 _d30808081